Vendor source

Reviewed 21 Jul 2026

Completeness Strong (75%)

Ki-67 APP, Breast Cancer

Visiopharm

Our Ki-67 solution for breast cancer is fully automated and does not require manual input during analysis. The solution consists of four automated analysis steps. Once started, it automatically separates the sample tissue from control tissues and robustly identifies invasive cancer areas in the sample. Tumor nuclei are counted based on their Ki-67 expression and the resulting proliferation index for the whole tumor area is calculated.

Supported by 8 papers

Key features

Calculation of the proliferation index

Counting of all tumor cells

Counting of positively stained tumor cells

General Information

Product name

Ki-67 APP, Breast Cancer

Company

Modality

Histopathology

Main task

Scoring (IHC quantification)

Subspeciality

Breast pathology

Organ/Specimen source

Not specified

Disease targeted

Breast cancer

Specimen type

Biopsy(ies), Resection(s)

Staining

IHC

Stain subtype

KI-67

Regulatory Information

CE-IVD Certification

Pathway:

In Vitro Diagnostic Regulation (IVDR)

Class:

Class C

Verified by Health AI Register

Scanner Brands Certified for Use (CE-IVD)

HAMAMATSU, GE

Scanner Models Certified for Use (CE-IVD)

HAMAMATSU NANOZOOMER 2.0-HT, GE OMNYX VL4, GE OMNYX VL120

Other certifications

Not specified

Technical Specifications

Patient population age

Not specified

Input

whole slide image, 20x magnification

Input format

DICOM, MRXS, NDPI, SVS, TIFF

Output

segmentation overlay, proliferation index as Percent of the positively stained tumor cells, total number of tumor cells

Output format

Not specified

Integration

Integration via AI marketplace or distribution platform, Integration with IMS (Image Management System), Integration with LMS (Laboratory Management System), Stand-alone third party application

Deployment

Cloud-based, Hybrid, Locally on dedicated hardware, Locally virtualized (virtual machine, docker)

Trigger for analysis

Automatically, right after the image acquisition, On demand, On demand, triggered by a user through e.g. a button click, image upload

Processing time

1 - 10 minutes

Population

Breast Cancer patients

Viewer systems

Not specified

Market Presence

On market since

04-2023

AI Platforms

Paige, Philips, Proscia, Sectra Amplifier Store

Resellers

Agilent, Proscia

Countries present

EU, UK

Paying clinical customers

Not specified

Research/test users

Not specified

Pricing Information

Pricing model

Subscription

Based on

Number of analyses

Source: Vendor | First published: Jul 30, 2025 | Last updated: Jul 21, 2026